ReviewMicroorganisms2021
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics.Molecular biology reports · 2026Review
- Essential role of glycogen synthase kinase 3 in regulating growth, drug response, and infectivity inAntimicrobial agents and chemotherapy · 2026Article
- The atypical dual-specificity protein phosphatase (DUSP)/kinatase of Leishmania infantum modulates infectivity, oxidative stress response and antimonial resistance.PLoS neglected tropical diseases · 2026Article
- Protein Kinase Inhibitors and Oxidative Stress Modulate In Vivo Phosphorylation ofPharmaceutics · 2026Article
- Whole-Genome Sequencing and Comparative Genomic Analysis ofMicroorganisms · 2026Article
- Resequencing and De Novo Assembly ofPathogens (Basel, Switzerland) · 2026Article
- Manipulation of macrophage signaling byVirulence · 2025Review
- Recent advances in structural modifications of natural products for anti-leishmaniasis therapy (2010-2024).RSC medicinal chemistry · 2025Review
- Genome-Wide Identification of Novel miRNAs and Infection-Related Proteins inPathogens (Basel, Switzerland) · 2025Article
- Identification of MAPK3 inhibitors againstJournal of veterinary science · 2025Article
- Hit-to-Lead Studies of Pyrazinylpiperazines against Visceral Leishmaniasis: Pharmacokinetic Profile andACS pharmacology & translational science · 2025Article
- Protein phosphorylation networks in Baylisascaris procyonis revealed by phosphoproteomic analysis.Parasites & vectors · 2025Article
- Recombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.Infectious diseases of poverty · 2025Article
- The potential ofMicrobiology spectrum · 2025Article
- Activity-based chemoproteomic profiling reveals the active kinome ofFrontiers in pharmacology · 2025Article
- Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid.Pharmaceutics · 2023Article
- How many kinases are druggable? A review of our current understanding.The Biochemical journal · 2023Article
- Triose Phosphate Isomerase Structure-Based Virtual Screening and In Vitro Biological Activity of Natural Products asPharmaceutics · 2023Article
- In Vitro and In Silico Studies of Kinase Inhibitor of MAPK3 Protein to Determine Leishmania martiniquensis Treatment.Acta parasitologica · 2023Article
- Imidazo[1,2-a]pyridine: a Highly Potent Therapeutic Agent Clears Piroplasm Infection In Vitro.Acta parasitologica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.